Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has announced a non-brokered private placement offering of up to 50,000,000 units at C$0.02 per unit, aiming to raise up to C$1,000,000. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of one common share at C$0.05 within 24 months of closing.
The company has begun receiving commitments for the placement, according to COO Dr. Rahul Kushwah. The proceeds will be allocated to general working capital and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors. All securities issued will have a four-month and one-day statutory hold period.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.